Sanofi’s eczema drug hits primary endpoint in PhIIb trial, plans underway for PhIII in 2024

13 Oct 2023

Phase 2Clinical ResultAcquisitionPhase 3

Sanofi’s anti-OX40L antibody, amlitelimab, passed a 390-patient Phase IIb trial by hitting the primary endpoint, with patients seeing up to a 61.5% improvement on a scale used to measure eczema severity, the company said at the European Academy of Dermatology and Venereology Congress. Sanofi rolled out detailed data from its dose-ranging STREAM-AD trial on Friday, paving the way for a Phase III study in the first half of next year and bolstering the company’s immunology portfolio. Sanofi first got its hands on the drug when it bought out Kymab in 2021 for $1.5 billion, with amlitelimab as the top candidate in the deal.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Sanofi

Kymab Ltd.

Indications

Eczema

Targets

Drugs

BrivekimigAmlitelimab

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.